In vivo type 1 cannabinoid receptor availability in Alzheimer's disease

European Neuropsychopharmacology

Volumn 24, Issue 2, 2014, Pages 242-250

  Ahmad, Rawaha ^a,b   Goffin, Karolien ^a,b   Van den Stock, Jan ^a,c   De Winter, François Laurent ^a,c   Cleeren, Evy ^a,b   Bormans, Guy ^c   Tournoy, Jos ^a,c   Persoons, Philippe ^a,c   Van Laere, Koen ^a,b   Vandenbulcke, Mathieu ^a,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; Amyloid; ApoE; Cannabinoid receptor; MMSE; PET scan

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; CANNABINOID 1 RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; VERY ELDERLY;

ALZHEIMER'S DISEASE; AMYLOID; APOE; CANNABINOID RECEPTOR; MMSE; PET SCAN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BENZOTHIAZOLES; BRAIN; COGNITION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, CANNABINOID, CB1;

EID: 84893687955     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.10.002     Document Type: Article

References (48)

1. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
2. Albinski R., Kleszczewska-Albinska A., Bedynska S. [Geriatric Depression Scale (GDS). Validity and reliability of different versions of the scale-review]. Psychiatr. Pol. 2011, 45:555-562.
3. Aso E., Palomer E., Juves S., Maldonado R., Munoz F.J., Ferrer I. CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP/PS1 mice. J. Alzheimer's Dis.: JAD 2012, 30:439-459.
4. Balthazar M.L., Yasuda C.L., Cendes F., Damasceno B.P. Learning, retrieval, and recognition are compromised in aMCI and mild AD: are distinct episodic memory processes mediated by the same anatomical structuresα. J. Int. Neuropsychol. Soc. 2010, 16:205-209.
5. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 2003, 23:11136-11141.
6. 18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc. Nat. Acad. Sci. U.S.A 2007, 104:9800-9805.
7. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
8. Cummings J.L. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997, 48:S10-S16.
9. Davies S.N., Pertwee R.G., Riedel G. Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 2002, 42:993-1007.
10. Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
11. Farkas S., Nagy K., Palkovits M., Kovacs G.G., Jia Z., Donohue S., Pike V., Halldin C., Mathe D., Harkany T., Gulyas B., Csiba L. [(125)I]SD-7015 reveals fine modalities of CB(1) cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. Neurochem. Int. 2012, 60:286-291.
12. Galasko D., Bennett D., Sano M., Ernesto C., Thomas R., Grundman M., Ferris S. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis. Assoc. Disord. 1997, 11(Suppl 2):S33-S39.
13. Garcia-Arencibia M., Garcia C., Fernandez-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8:432-439.
14. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000, 97:505-519.
15. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993, 56:523-527.
16. Horti A.G., Fan H., Kuwabara H., Hilton J., Ravert H.T., Holt D.P., Alexander M., Kumar A., Rahmim A., Scheffel U., Wong D.F., Dannals R.F. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J. Nucl. Med. 2006, 47:1689-1696.
17. Karrasch M., Myllyniemi A., Latvasalo L., Soderholm C., Ellfolk U., Laine M. The diagnostic accuracy of an incidental memory modification of the Boston Naming Test (memo-BNT) in differentiating between normal aging and mild Alzheimer's disease. Clin. Neuropsychol. 2010, 24:1355-1364.
18. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
19. Lastres-Becker I., Cebeira M., De Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., Fernandez-Ruiz J.J. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 2001, 14:1827-1832.
20. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
21. Lee J.H., Agacinski G., Williams J.H., Wilcock G.K., Esiri M.M., Francis P.T., Wong P.T., Chen C.P., Lai M.K. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem. Int. 2010, 57:985-989.
22. Mathis C.A., Kuller L.H., Klunk W.E., Snitz B.E., Price J.C., Weissfeld L.A., Rosario B.L., Lopresti B.J., Saxton J.A., Aizenstein H.J., McDade E.M., Kamboh M.I., DeKosky S.T., Lopez O.L. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann. Neurol. 2013, 73:751-761.
23. Mazzola C., Micale V., Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 2003, 477:219-225.
24. Morera-Herreras T., Miguelez C., Aristieta A., Ruiz-Ortega J.A., Ugedo L. Endocannabinoid modulation of dopaminergic motor circuits. Front. Pharmacol. 2012, 3:110.
25. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
26. Nelissen N., Vandenbulcke M., Fannes K., Verbruggen A., Peeters R., Dupont P., Van Laere K., Bormans G., Vandenberghe R. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007, 130:2055-2069.
27. O'Bryant S.E., Humphreys J.D., Smith G.E., Ivnik R.J., Graff-Radford N.R., Petersen R.C., Lucas J.A. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch. Neurol. 2008, 65:963-967.
28. Pazos M.R., Sagredo O., Fernandez-Ruiz J. The endocannabinoid system in Huntington's disease. Curr. Pharm. Des. 2008, 14:2317-2325.
29. Perez D.M., Karnik S.S. Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. 2005, 57:147-161.
30. Quarantelli M., Berkouk K., Prinster A., Landeau B., Svarer C., Balkay L., Alfano B., Brunetti A., Baron J.C., Salvatore M. Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction. J. Nucl. Med. 2004, 45:192-201.
31. Ramirez B.G., Blazquez C., Gomez del P.T., Guzman M., De Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
32. Reibaud M., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A. Enhancement of memory in cannabinoid CB1 receptor knock-out mice. Eur. J. Pharmacol. 1999, 379:R1-R2.
33. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Nat. Acad. Sci. U.S.A 2004, 101:284-289.
34. Rodriguez J.J., Noristani H.N., Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog. Neurobiol. 2012, 99:15-41.
35. Sanabria-Bohorquez S.M., Hamill T.G., Goffin K., De L.I., Bormans G., Burns H.D., Van L.K. Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:920-933.
36. Skinner J., Carvalho J.O., Potter G.G., Thames A., Zelinski E., Crane P.K., Gibbons L.E. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012, 6:489-501.
37. Solas M., Francis P.T., Franco R., Ramirez M.J. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 2013, 34:805-808.
38. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., Soubrie P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology (Berl) 1996, 126:165-172.
39. Terry G., Liow J.S., Chernet E., Zoghbi S.S., Phebus L., Felder C.C., Tauscher J., Schaus J.M., Pike V.W., Halldin C., Innis R.B. Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 2008, 41:690-698.
40. Van der Elst W., van Boxtel M.P., van Breukelen G.J., Jolles J. Rey's verbal learning test: normative data for 1855 healthy participants aged 24-81 years and the influence of age, sex, education, and mode of presentation. J. Int. Neuropsychol. Soc.: JINS 2005, 11:290-302.
41. Van Laere K., Casteels C., Dhollander I., Goffin K., Grachev I., Bormans G., Vandenberghe W. Widespread decrease of type 1 cannabinoid receptor availability in huntington disease in vivo. J. Nucl. Med. 2010, 51:1413-1417.
42. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J., Bormans G. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008, 39:1533-1541.
43. Van Laere K., Nuttin B., Gabriels L., Dupont P., Rasmussen S., Greenberg B.D., Cosyns P. Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J. Nucl. Med. 2006, 47:740-747.
44. Videaud H., Torny F., Prado-Jean A., Couratier P. Use of the Visual Object and Space Perception (VOSP) test battery in two cases of posterior cortical atrophy. Neurocase 2008, 15:32-36.
45. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
46. Walsh S., Mnich K., Mackie K., Gorman A.M., Finn D.P., Dowd E. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res. Bull. 2010, 81:543-548.
47. Walther S., Mahlberg R., Eichmann U., Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006, 185:524-528.
48. Westlake T.M., Howlett A.C., Bonner T.I., Matsuda L.A., Herkenham M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 1994, 63:637-652.